Phase 2 N=36 Trial to Evaluate Efficacy and Safety of Pembrolizumab and Gemcitabine in HER2-negative ABC
Advanced Breast Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) Within the First Cycle — 1 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=25 Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm
Parkinson Disease
Primary: Change in Quantitative Biomechanics 1 (Clinical Motor Ratings MDS-UPDRS) — 38; 34; 28; 36.75 units on a scale — p=0.391
Phase 2 N=154 A Study of ADX-102 in Subjects With Allergic Conjunctivitis
Conjunctivitis, Allergic
Primary: Ocular Itching Evaluated by the Subject at 10(±1) Minutes Post the Ora Calibra® Conjunctival Allergen Challenge at Day 15. — 2.020; 2.398; 2.515 units on a scale
Phase 2 N=42 Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
Advanced Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
Primary: Objective Response Rate (ORR) — 2 percentage of participants
Phase 2 N=9 An Open-label Study of APX001 for Treatment of Patients With Candidemia/Invasive Candidiasis Caused by Candida Auris
Candidemia · Invasive Candidiases · Candida Infection
Primary: Percentage of Participants With Treatment Success at End of Study Treatment (EOST) as Determined by Data Review Committee (DRC) — 88.9 Percentage of participants
Phase 2 N=10 Pirfenidone for Restrictive Chronic Lung Allograft Dysfunction
Restrictive Chronic Lung Allograft Dysfunction · Lung Transplant Rejection
Primary: Tolerability of Pirfenidone — 3 Participants
Phase 2 N=109 Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
Diabetes Mellitus, Type 1 · Diabetes Mellitus · Autoimmune Diseases
Primary: Change in Stimulated C-peptide During a MMTT — 0.551; 0.506; 0.663; 0.425 Unitless back-transformed from log-scale — p== 0.5009
Phase 2 N=153 OTO-313 in Subjects With Unilateral Subjective Tinnitus
Subjective Tinnitus
Primary: Percentage of Tinnitus Functional Index (TFI) Responders at Weeks 4 and at Week 8 — 20; 27 Participants — p==0.385
Phase 2 N=25 A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Participants With Controlled Blood Pressure
Mild Hypertension
Primary: Percent Change From Baseline in Plasma Angiotensinogen (AGT) at Day 43 (Week 7) Compared to Placebo — 12.6; -54.2 percent change — p=<0.001
Phase 2 N=1,541 A Study of Ad26.COV2.S Administered as Booster Vaccination in Adults Who Have Previously Received Primary Vaccination With Ad26.COV2.S or BNT162b2
Coronavirus Disease
Primary: Cohort 1: Percentage of Participants With Serological Response Against SARS-CoV-2 Original Strain 14 Days After Ad26.COV2.S Booster Vaccination After Completing Primary…
Phase 2 N=60 Feasibility Study of Intraoperative Imaging in Breast Cancer
Breast Cancer
Primary: (Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials — 2.1; 4.7; 4.2 Ratio
Phase 2 N=306 Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors
Ovarian Cancer · Cervical Cancer · Endometrial Cancer
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) for Dose-escalation Part — 0; 0; 0; 0 Participants
Phase 2 N=86 Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
Coronavirus Disease 2019
Primary: Mean Change From Baseline in Total Symptom Score — -3.4; -3.5 units on a scale — p=0.818
Phase 2 N=458 A Study to Evaluate the Efficacy and Safety of Vonoprazan Compared to Placebo in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
Non-Erosive Gastro-Esophageal Reflux Disease · Heartburn
Primary: Percentage of Evaluable Heartburn Episodes Completely Relieved Within 3 Hours and With No Further Heartburn Reported for 24 Hours After Taking Study Drug — 56.0; 60.6…
Phase 2 N=192 A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure
Diastolic Heart Failure
Primary: Change From Baseline in Treadmill Exercise Time at Maintenance Phase Week 24 — 424.5; 485.0; 89.5; 37.0 Seconds — p=0.0302